Holen Sie sich die Stockscreener-App
542.12
2.43%
-13.48
Handel nachbörslich:
536.98
-5.14
-0.95%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$555.60
Offen:
$562.71
24-Stunden-Volumen:
270.55K
Relative Volume:
0.77
Marktkapitalisierung:
$12.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-21.58
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+5.28%
1M Leistung:
+23.22%
6M Leistung:
+85.18%
1J Leistung:
+70.97%
1-Tages-Spanne:
$540.01
$571.16
1-Wochen-Bereich:
$505.00
$577.90
52-Wochen-Spanne:
$265.00
$577.90
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
542.12 | 12.62B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Madrigal Pharmaceuticals (NASDAQ: MDGL) grants 2,125 RSUs to hires under inducement plan - Stock Titan
Jefferies 25: The Cardiometabolic Revolution Is Going Global - Citeline News & Insights
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating - MarketScreener
What margin trends mean for Madrigal Pharmaceuticals Inc. stockChart Signals & Momentum Based Trading Ideas - newser.com
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target - GuruFocus
Oppenheimer raises Madrigal Pharmaceuticals stock price target on positive Rezdiffra data - Investing.com Canada
Will Madrigal Pharmaceuticals Inc. stock pay special dividendsJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Madrigal Pharmaceuticals Inc. (YDO1) stock in buy zone after pullbackPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
How Madrigal Pharmaceuticals Inc. (YDO1) stock reacts to Fed tighteningJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Why Madrigal Pharmaceuticals Inc. (YDO1) stock is listed among top recommendationsTrade Ideas & Real-Time Price Movement Reports - newser.com
Madrigal Pharmaceuticals stock price target raised by Truist on MASH potential - Investing.com South Africa
Can Madrigal Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating - MarketScreener
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Short Interest & Long-Term Safe Investment Plans - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth storyWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceMarket Growth Report & Fast Gain Stock Tips - newser.com
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones - Yahoo Finance
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis - Yahoo Finance
Will Madrigal Pharmaceuticals Inc. (YDO1) stock sustain dividend payoutsWall Street Watch & Low Risk High Reward Ideas - newser.com
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning - MyChesCo
Madrigal Pharmaceuticals stock hits all-time high at 545.0 USD By Investing.com - Investing.com UK
Madrigal Pharma (NASDAQ: MDGL) sets fireside chats at three investor conferences - Stock Titan
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Madrigal Pharmaceuticals (BIT:1MDGL) Price Target Increased by 11.64% to 485.78 - Nasdaq
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):